Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer
Immunogenic cell death (ICD), an immune-priming form of cell death, has been shown to be induced by several different anti-cancer therapies. Despite being the first and one of the most successful antibody-drug conjugates (ADCs) approved for refractory HER2-positive breast cancer, little is known if response and resistance to trastuzumab emtansine (T-DM1) involves ICD modulation that can be leveraged to enhance T-DM1 response. Here, we report that T-DM1 induces spindle assembly checkpoint (SAC)-dependent ICD in sensitive cells by inducing eIF2α phosphorylation, surface exposure of calreticulin, ATP and HMGB1 release, and secretion of ICD-related cytokines, all of which are lost in resistance. Accordingly, an ICD-related gene signature correlates with clinical response to T-DM1-containing therapy. We found that transforming acidic coiled-coil containing 3 (TACC3) is overexpressed in T-DM1 resistant cells, and that T-DM1 responsive patients have reduced TACC3 protein while the non-responders exhibited increased TACC3 expression during T-DM1 treatment. Notably, genetic or pharmacological inhibition of TACC3 revives T-DM1-induced SAC activation and induction of ICD markers in vitro. Finally, TACC3 inhibition elicits ICD in vivo shown by vaccination assay, and it potentiates T-DM1 by inducing dendritic cell (DC) maturation and enhancing infiltration of cytotoxic T cells in the human HER2-overexpressing MMTV.f.huHER2#5 (Fo5) transgenic model. Together, our results show that ICD is a key mechanism of action of T-DM1 which is lost in resistance, and that targeting TACC3 restores T-DM1-mediated ICD and overcomes resistance.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2023) vom: 14. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gedik, Mustafa Emre [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibody drug conjugate |
|---|
| Anmerkungen: |
Date Revised 21.02.2024 published: Electronic UpdateIn: Cancer Res. 2024 Feb 6;:. - PMID 38319231 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2023.09.12.557273 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362418187 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362418187 | ||
| 003 | DE-627 | ||
| 005 | 20240222091351.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.09.12.557273 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1301.xml |
| 035 | |a (DE-627)NLM362418187 | ||
| 035 | |a (NLM)37745348 | ||
| 035 | |a (PII)2023.09.12.557273 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gedik, Mustafa Emre |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Cancer Res. 2024 Feb 6;:. - PMID 38319231 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Immunogenic cell death (ICD), an immune-priming form of cell death, has been shown to be induced by several different anti-cancer therapies. Despite being the first and one of the most successful antibody-drug conjugates (ADCs) approved for refractory HER2-positive breast cancer, little is known if response and resistance to trastuzumab emtansine (T-DM1) involves ICD modulation that can be leveraged to enhance T-DM1 response. Here, we report that T-DM1 induces spindle assembly checkpoint (SAC)-dependent ICD in sensitive cells by inducing eIF2α phosphorylation, surface exposure of calreticulin, ATP and HMGB1 release, and secretion of ICD-related cytokines, all of which are lost in resistance. Accordingly, an ICD-related gene signature correlates with clinical response to T-DM1-containing therapy. We found that transforming acidic coiled-coil containing 3 (TACC3) is overexpressed in T-DM1 resistant cells, and that T-DM1 responsive patients have reduced TACC3 protein while the non-responders exhibited increased TACC3 expression during T-DM1 treatment. Notably, genetic or pharmacological inhibition of TACC3 revives T-DM1-induced SAC activation and induction of ICD markers in vitro. Finally, TACC3 inhibition elicits ICD in vivo shown by vaccination assay, and it potentiates T-DM1 by inducing dendritic cell (DC) maturation and enhancing infiltration of cytotoxic T cells in the human HER2-overexpressing MMTV.f.huHER2#5 (Fo5) transgenic model. Together, our results show that ICD is a key mechanism of action of T-DM1 which is lost in resistance, and that targeting TACC3 restores T-DM1-mediated ICD and overcomes resistance | ||
| 650 | 4 | |a Preprint | |
| 650 | 4 | |a Immunologic cell death | |
| 650 | 4 | |a T-DM1 | |
| 650 | 4 | |a TACC3 | |
| 650 | 4 | |a antibody drug conjugate | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a mitotic arrest | |
| 700 | 1 | |a Saatci, Ozge |e verfasserin |4 aut | |
| 700 | 1 | |a Oberholtzer, Nathaniel |e verfasserin |4 aut | |
| 700 | 1 | |a Uner, Meral |e verfasserin |4 aut | |
| 700 | 1 | |a Akbulut, Ozge |e verfasserin |4 aut | |
| 700 | 1 | |a Cetin, Metin |e verfasserin |4 aut | |
| 700 | 1 | |a Aras, Mertkaya |e verfasserin |4 aut | |
| 700 | 1 | |a Ibis, Kubra |e verfasserin |4 aut | |
| 700 | 1 | |a Caliskan, Burcu |e verfasserin |4 aut | |
| 700 | 1 | |a Banoglu, Erden |e verfasserin |4 aut | |
| 700 | 1 | |a Wiemann, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Uner, Aysegul |e verfasserin |4 aut | |
| 700 | 1 | |a Aksoy, Sercan |e verfasserin |4 aut | |
| 700 | 1 | |a Mehrotra, Shikhar |e verfasserin |4 aut | |
| 700 | 1 | |a Sahin, Ozgur |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2023) vom: 14. Sept. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:14 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.09.12.557273 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 14 |c 09 | ||